What Researchers Did
The authors reviewed recent research on calcific uraemic arteriolopathy (also called calciphylaxis), a rare condition in people with chronic kidney disease, and the treatments being used for it.
What They Found
This narrative review of calcific uraemic arteriolopathy found that the condition is a rare but important cause of illness and death in people with chronic kidney disease, and that its prevalence is increasing in patients with renal failure. The condition is also being recognized in people without kidney failure. The review describes growing understanding of how blood vessel calcification happens, including the role of the uraemic microenvironment in turning vascular smooth muscle cells into bone-forming cells. Newer treatments for high phosphate and secondary hyperparathyroidism, including bisphosphonates, newer phosphate binders and case reports of cinacalcet, have begun to be used in these patients. The abstract also lists hyperbaric oxygen and sodium thiosulphate as other treatments not aimed directly at calcium and phosphate balance.
What This Means for Canadian Patients
For people with calciphylaxis, the review suggests clinicians should consider combining newer drugs that treat calcium and phosphate problems with older approaches for promoting wound healing, such as hyperbaric oxygen and sodium thiosulphate infusions. The abstract does not give a session number, pressure or results for hyperbaric oxygen, so it does not show how well it works. Patients should talk with their kidney care team about which options fit their situation.
Canadian Relevance
No direct Canadian connection identified.
Study Limitations
The abstract states that randomized controlled trials for treatments in this condition are still lacking, and it mentions cinacalcet only as case reports, so the treatment suggestions are not backed by controlled trial evidence.